European Commission logo
English English
CORDIS - EU research results

DosiKit, a first portable field medical device for fast triage of people after external irradiation

Project description

Dosing kit for nuclear accident victims

There is currently a lack of irradiation biodosimetry tools that can be used in the event of nuclear accidents where individuals are exposed to potentially dangerous levels of radiation. There are also no devices that can be used by non-specialists in the field to give immediate results in cases of partial-body irradiation (PBI). The EU-funded DosiKit project has developed a device and a fast test that can identify and classify irradiated individuals in the field after nuclear accidents. The project hopes to make the device available in 2022 in Europe after some important regulatory and risk assessment studies.


Acubens was founded in 2014, to develop and commercialize new game-changer medical diagnostic devices around NRBC emergency. Our team gathers young and experimented doctors, and seasoned business managers, uniting their competencies to develop nuclear/radiological/biological innovative transportable biodosimetry devices. Nuclear/radiological accident can expose individuals to radiation, with the need for fast triage of potentially exposed people requiring immediate medical care. There is today a lack of irradiation biodosimetry tools that can be used in the field, by non-specialist staff, giving immediate results and exposure cartography in case of Partial-Body irradiation (PBI).
To fulfil this critical unmet need for better initial crisis management, we invented the DosiKit device and fast test (45 minutes) to identify and classify irradiated individuals, directly in the field. This development was initiated in 2009 by the French Atomic Energy Commission within the European Commission program, BOOSTER (‘BiO-dOSimetric Tools for triagE to Responders’), and then continued by Acubens.
DosiKit technology is protected by 3 international patents and has reached TRL6 with a prototype validated in a large-scale exercise performed with the French army. Several collaborations are undergoing for biological validation with French research institute and hospitals.
Scientific and technical development was published in 3 scientific publications and many international oral communications. A strong contact has established with French, Germany, Israel, US and Singapore armies (LoI).
This DosiKit product will be on the market in 2022, starting in Europe and then extending worldwide. Forecasted sales revenue is 15 M€ in 2024.
The objectives of this phase 1 SME-Instrument are: (1) the final Biological and Technological validation of the device, (2) IP, FTO, Regulatory and risk assessment studies and (3) a market survey in Europe and USA to schedule our commercial actions.


Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00
92160 Nanterre

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Ile-de-France Ile-de-France Hauts-de-Seine
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 71 429,00